Why is Natco Pharma Ltd. falling/rising?

Market Outperformance Drives Investor Confidence

Natco Pharma’s recent price surge is underpinned by its impressive returns relative to the benchmark Sensex. Over the past week, the stock has surged by 8.42%, sharply contrasting with the Sensex’s decline of 2.53%. This trend extends over longer periods as well, with the stock delivering a 22.47% gain in the last month while the Sensex fell 7.20%. Year-to-date, Natco Pharma has appreciated by 14.76%, whereas the Sensex has declined by 8.23%. Such consistent outperformance highlights the market’s favourable view of the company’s prospects amid broader market volatility.

Moreover, the stock is trading close to its 52-week high, just 2.18% shy of the peak price of ₹1,059.6. On 10-Mar, it touched an intraday high of ₹1,051.2, marking a 4.89% increase from the previous close. This proximity to the yearly high signals strong buying interest and positive momentum among investors.

Technically, Natco Pharma is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical strength often attracts momentum traders and institutional investors, further supporting the stock’s upward trajectory.

Fundamental Strengths Bolster Share Price Gains

Natco Pharma’s rise is also supported by its solid fundamental profile. The company boasts a high return on equity (ROE) of 16.25%, indicating efficient management and effective utilisation of shareholder capital. This level of profitability is attractive to investors seeking companies with strong operational performance.

Additionally, the company maintains a low debt-to-equity ratio, averaging zero, which reduces financial risk and enhances its balance sheet strength. Such a conservative capital structure is often favoured in uncertain market conditions, contributing to investor confidence.

Valuation metrics further reinforce the stock’s appeal. With an ROE of 17.8 and a price-to-book value of 2.1, Natco Pharma is trading at a fair valuation relative to its historical averages and peer group. Despite a 16.5% decline in profits over the past year, the stock has still generated a robust 27.76% return during the same period, reflecting market optimism about its future earnings potential and strategic positioning.

Institutional investors hold a significant 20.55% stake in the company, and their share has increased by 0.59% over the previous quarter. This rising institutional interest suggests that well-informed market participants view Natco Pharma favourably, which often acts as a catalyst for further price appreciation.

Liquidity remains adequate, with the stock’s average traded value supporting trade sizes of approximately ₹4.12 crores, ensuring that investors can enter and exit positions without significant price disruption. However, it is worth noting that delivery volumes on 9-Mar fell by 11.5% compared to the five-day average, indicating a slight decline in investor participation despite the price rise.

Long-Term Performance Validates Current Momentum

Looking beyond short-term gains, Natco Pharma has demonstrated strong market-beating performance over multiple time horizons. Over the past three years, the stock has appreciated by 86.92%, significantly outperforming the Sensex’s 32.25% gain. Even over five years, the stock has delivered a respectable 25.59% return, underscoring its resilience and growth potential.

This sustained outperformance, combined with the company’s attractive valuation and solid fundamentals, explains the current upward momentum in its share price. Investors appear to be rewarding Natco Pharma for its consistent delivery and strategic positioning within the pharmaceutical sector.

In summary, Natco Pharma’s share price rise on 10-Mar is driven by a combination of strong relative returns, proximity to 52-week highs, robust technical indicators, and sound fundamental metrics. While some caution is warranted due to falling profits and reduced delivery volumes, the overall market sentiment remains positive, supported by increasing institutional interest and a healthy balance sheet.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →